Chemical modifications of the carboxyl group in the alanine moiety of pradimicin A were performed and in vitro and in vivo antifungal activities of the derivatives were examinedin comparison with those of pradimicin A. The amide derivatives showedactivities comparable to pradimicin A, indicating that the free carboxyl group can be modified without impairing the antifungal activity.
Pradimicin A (1), which was isolated from the culture broth of Actinomadura hibisca PI57-2, is the predecessor of benzo [a] naphthacenequinone antifungal antibiotics1~3). It exhibited broad-spectrum antifungal activity including activity against clinically important Candida, Aspergillus and Cryptococcus species40. Although pradimicin A is relatively non-toxic when compared with amphotericin B, its poor solubility in aqueous media posed some problems in further development. As part of our program aimed at obtaining more water soluble and potent pradimicin derivatives5), the alanine moiety of pradimicin A was modified chemically.
In this paper, we present synthesis and in vitro antifungal activities of pradimicin A derivatives, and in vivo efficacies of selected compoundsin mouse fungal infection models. 
4d (L-lysyl) and 4e (glycyl), were prepared by coupling of iV-benzyloxycarbonyl (TV-Cbz)-l active ester and appropriate amino esters followed by deblocking.
All the compounds gave satisfactory spectroscopic data (UV, IR, MS and XH NMR).
Biological Activities
The in vitro antifungal activities of the pradimicin A derivatives were determined by the The PD50 was calculated from the survival rate 20 days after the fungal challenge.
Inoculum size:
10LD50.
Single administration immediately after the fungal challenge. Twice a day for two consecutive days beginning immediately after the fungal challenge.
broth dilution method in Sabouraud dextrose mediumand by the agar dilution method on Sabouraud dextrose agar. MICs are summarized in Table 1 . The in vivo activities of the selected derivatives were evaluated in mice infected systemically with Candida albicans A9540. Groups of 5 mice at each dose level were infected with 10 LD50 of C. albicans A9540 and then the pradimicin derivatives were given either by im or iv administration. The results are shown in Table 2 . MAR. 1993 The amide derivatives, 3a, 3b and 3c, were effective in protecting mice from lethal infection as predicted from their MICvalues. The longer alkyl amide 3d and dipeptidyl derivatives, 4a, 4b, 4c and 4d, on the other hand, were almost inactive in vitro and in vivo. Esters 2a and 2b were inactive in vitro but showed efficacy in vivo against C. albicans infection. Detection of 1 (3/ig/ml) in plasma 18 hours after im administration of 2a at 50mg/kg dose indicated that these esters might serve as prodrugs and release 1 invivo.
These pradimicin A derivatives did not show oral activity in mice even at an oral dose of 50mg/kg Discussion Pradimicin A is an amphoteric compoundhaving basic amino and acidic carboxyl functionalities. The activity of benanomicin A and BMS-181184suggest that the amino group in the sugar moiety is not essential for the antifungal activity8 '9) . The purpose of the present study was to examine the role of the carboxyl group in the alanine side chain of pradimicin A. The results show that the carboxyl group can be modified without impairing antifungal activity. The amide 3a and the small alkyl amide derivatives 3b and 3c are as effective as the parent compound, giving PD50 values comparable to that of 1. But the fact that butyl amide derivative 3d and dipeptidyl derivatives 4a~4d showed much reduced activity indicates that only small (alkyl) amide functionalities can act as bioisoteres of the carboxyl group in 1. Unfortunately, however, those bioactive amide derivatives appear not suitable for iv formulations owing to their limited solubility in saline at physiological pH values.
Experimental General
Mp's were determined with a Yanaco micro melting point apparatus and are uncorrected. UVand IR spectra were recorded on a JASCOUVIDEC-610C spectrometer and a JASCOIR-810 spectrometer, respectively. *H NMR spectra were recorded on a JEOLJNM-GX400 spectrometer. Mass spectra were obtained with a JEOL JMS-AX505Hspectrometer or HITACHIM80Bspectrometer.
Pradimicin A Methyl Ester (2a) 1 HC1 salt (105mg) was refluxed in 20.5ml of 0.04n methanolic HC1 for 1.5 hours. The reaction mixture was cooled and concentrated to dryness to yield 2a HC1 salt (108mg). An aqueous solution of the HC1 salt (15mg) was adjusted to pH 5.0 to deposit 2a (12mg). MP: 236~239°C (dec). IR vmax (KBr) cm "1 3380, 1740, 1625, 1440, 1255 . UV lmax (0.02n NaOH-MeOH (1:1)) nm (e) 241 (27,400), 320 (12,700), 497(ll,200 Pradimicin A Ethyl Ester (2b) To a stirred solution of 1 HC1 salt (290mg) in 50ml of EtOH was added dropwise 3ml of thionyl chloride at 0°C. The stirring was continued for one hour at 0°C, and two hours at room temperature. The reaction mixture was concentrated to dryness and the residue was chromatographed on a reversed phase silica gel column (YMCODSA60, 20mmi.d. x 320mm). Elution was carried out with a mixture of acetonitrile -0.15% KH2PO4, pH 3.5 (50 : 50). The fractions containing pure 2b were pooled, concentrated and desalted by Diaion HP-20 chromatography (100ml, eluent : acetone-1 n HC1, pH 3.0) to yield 2b HC1 salt (263mg). An aqueous solution of the HC1 salt (60mg) was adjusted to pH 6.0 to deposit 2b (50mg [5,4,0]-7-undecene (48 /^1) were added to a stirred solution of 1 Na salt (250mg) and K2CO3(22mg) in 20ml of DMSOat 5°C. The stirring was continued for one hour at 5°C, and 55 hours at room temperature. The reaction mixture was diluted with water (400ml, pH 3.5 by 6n HC1), and then applied to a column of Diaion HP-20 (250ml, eluent : acetone-1 n HC1, pH 3.0) to yield semi-pure 2c HC1salt (221 mg). This material was applied to a column of reversed phase silica gel (LiChroprep RP-18, 20 mmi.d. x 450 mm). Elution was carried out with a mixture of acetonitrile -0.15% KH2PO4, pH3.5 (45 : 55) . The fractions containing pure 2c were pooled, concentrated and desalted by Diaion HP-20 chromatography (100ml) to yield 2c HC1 salt (77mg). An aqueous solution of the HC1 salt (10mg) was adjusted to pH 5.5 to deposit 2c (7mg). MP: 205~208°C (dec), IR vmax (KBr) cm "1 3380, 1755, 1625, 1440, 1255 . UV Amax (0.02n NaOH-MeOH (1 : 1)) Pradimicin A Amide (3a) A solution of 2a HC1salt (95mg) in 2ml MeOHwas added dropwise to a stirred solution of 28% ammonia (25 ml) and stirring was continued for 4 hours at room temperature. The solvent was evaporated and the solid residue was treated with 0.25n NaOHin aqueous MeOH(30ml) at room temperature for 4 hours. The solution was then acidified to pH 3.5 with 1 n HC1, concentrated and desalted by Diaion HP-20 column chromatography (150ml, eluent : acetone -1 n.HCI, pH 3.0) to yield semi-pure 3a HC1 salt (105 mg). The solid (100mg) was applied to a column of reversed phase silica gel (YMCODSA60, 20mmi.d. x 450 mm). Elution was carried out with a mixture ofacetonitrile -0.15% KH2PO4,pH 3.5 (21 : 79). The fractions containing pure 3a were pooled, concentrated and desalted by Diaion HP-20 chromatography (100 ml) to yield 3a HC1 salt (59mg). An aqueous solution of the HC1 salt was adjusted to pH 6.0 to deposit 3a (50mg). MP: 205~208dC (dec). IR vmax (KBr) cm"1 3400, 1620, 1440, 1250. UV Xmax (0.02n NaOH-MeOH (1 : 1)) nm (e) 245 (30,100), 320 (13,Q00), 496 (ll,800 Pradimicin A Methylamide (3b) 3b (1 17mg) was prepared by the procedure described for 3a except that starting 2a HC1 salt (160mg) was reacted with 40% aqueous methylamine (15ml). MP: 202~205°C (dec). IR vmax (KBr) cm"1 3400, 1620, 1440, 1290 . UV Amax (0.02n NaOH-MeOH (1 : 1) Pradimicin A Dimethylamide (3c)
A mixture of TV-Cbz-1 (224 mg)1O), 7V-hydroxysuccinimide (32 mg) and 1 ,3-dicyclohexylcarbodiimide (DCC, 58 mg) in THF (5 ml) was stirred for 1 hour at room temperature and the resulting precipitate was filtered off. The filtrate was added to a 50% aqueous solution of dimethylamine (0.04ml) and the mixture was stirred at room temperature overnight and then concentrated in vacuo. The residue was chromatographed on a silica gel column to yield 215mg of Af-Cbz-3c. A mixture of N-Cbz-3c (100mg), MeOH(6ml), water (1.5ml) and acetic acid (1.5ml) was stirred with 10% palladium on carbon (30mg) under hydrogen atmosphere overnight. The solid was filtered off and the filtrate was concentrated and purified on a reversed phase silica gel column (25mm i. 
D-Alanyl Pradimicin A (4a)
A suspension of D-alanine benzyl ester tosylate (1 16mg) and triethylamine (46/jl) in THF (2ml) was mixed with a solution of N-Cbz-1 (300mg), N-hydroxybenzotriazole (49mg) and DCC(68 mg) in THF (20ml). After the mixture was stirred for 2 hours at 0°C and then 13 hours at room temperature, it was diluted with water (100ml) and extracted with EtOAc (100ml). The organic solvent was evaporated to give a solid residue which was dissolved in a mixture of MeOH(30ml), EtOH(10ml) and water (20ml), and hydrogenated in the presence of 5%palladium on carbon for 15 hours. The catalyst was filtered off and the filtrate was concentrated and applied to a reversed phase silica gel column (LiChroprep PR-18, E. Merck, 22mm i.d. x 450mm). Elution was carried out with acetonitrile -0.15% KH2PO4, pH 3.5 (21 : 79) and fractions containing the homogeneousproduct were pooled, concentrated and desalted by Diaion
